729 related articles for article (PubMed ID: 18419422)
1. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
[TBL] [Abstract][Full Text] [Related]
2. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
4. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
Mira JA; Corzo JE; Rivero A; Macias J; De Leon FL; Torre-Cisneros J; Gomez-Mateos J; Jurado R; Pineda JA
Am J Trop Med Hyg; 2004 Mar; 70(3):298-301. PubMed ID: 15031520
[TBL] [Abstract][Full Text] [Related]
5. [Visceral leishmaniasis: a comparative study of patients with and without human immunodeficiency virus infection].
Reus S; Sánchez R; Portilla J; Boix V; Priego M; Merino E; Román F
Enferm Infecc Microbiol Clin; 1999 Dec; 17(10):515-20. PubMed ID: 10650648
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
[TBL] [Abstract][Full Text] [Related]
7. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV.
López-Vélez R
Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():143-7. PubMed ID: 14678641
[TBL] [Abstract][Full Text] [Related]
8. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
9. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus.
del Giudice P; Mary-Krause M; Pradier C; Grabar S; Dellamonica P; Marty P; Gastaut JA; Costagliola D; Rosenthal E;
J Infect Dis; 2002 Nov; 186(9):1366-70. PubMed ID: 12402211
[TBL] [Abstract][Full Text] [Related]
10. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
11. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.
Madec Y; Laureillard D; Pinoges L; Fernandez M; Prak N; Ngeth C; Moeung S; Song S; Balkan S; Ferradini L; Quillet C; Fontanet A
AIDS; 2007 Jan; 21(3):351-9. PubMed ID: 17255742
[TBL] [Abstract][Full Text] [Related]
12. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
13. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.
Hurissa Z; Gebre-Silassie S; Hailu W; Tefera T; Lalloo DG; Cuevas LE; Hailu A
Trop Med Int Health; 2010 Jul; 15(7):848-55. PubMed ID: 20487426
[TBL] [Abstract][Full Text] [Related]
15. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
Moh R; Danel C; Messou E; Ouassa T; Gabillard D; Anzian A; Abo Y; Salamon R; Bissagnene E; Seyler C; Eholié S; Anglaret X
AIDS; 2007 Nov; 21(18):2483-91. PubMed ID: 18025885
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
17. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
18. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
Bocket L; Cheret A; Deuffic-Burban S; Choisy P; Gerard Y; de la Tribonnière X; Viget N; Ajana F; Goffard A; Barin F; Mouton Y; Yazdanpanah Y
Antivir Ther; 2005; 10(2):247-54. PubMed ID: 15865219
[TBL] [Abstract][Full Text] [Related]
19. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
20. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
